Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
All content for Tomorrow’s World Today® Podcast is the property of Tomorrow's World Today® and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
Doorway to Innovation: Chamberlain Group’s Journey to AI-Powered Access
Tomorrow’s World Today® Podcast
24 minutes
4 months ago
Doorway to Innovation: Chamberlain Group’s Journey to AI-Powered Access
What does the future of home access look like? Jeff Meredith, CEO of Chamberlain Group, breaks down the strategy behind smarter garage tech and connected convenience. 🔧📶 Featured on: Tomorrow's World Today - S9E3 – Garage GuardiansLearn more about this topic: Smart Garage Door Systems Are Enhancing Home SecurityHow Chamberlain Group Aligns With Smart Home Security TrendsCollaborate with us! Support the show For more information about the innovations that are shaping tomorrow's world, head to ...
Tomorrow’s World Today® Podcast
Blood is the currency of clinical trials—and getting it from patient to lab within 48 hours can make or break a study. In this episode, LabConnect CEO Wes Wheeler joins us to discuss how a lab-agnostic model, purpose-built software, and disciplined process design are transforming global clinical research. Wes breaks down why LabConnect chooses not to own labs and how this decision enables speed, scale, and flexibility across seven key regions where trials are conducted and patients resi...
